Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
Publication Date: August 8, 2016
Key Points
Key Points
Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Assessment
Assessm...
...women with suspected stage IIIC or...
A primary clinical evaluation should includ...
Treatment
...reatmen...
...le 1. Risk Factors for Perioperative Morb...
...who have a high perioperative risk prof...
...at women are not eligible for medical or surgica...
...men who are fit for PCS, with potentially r...
...women with a high likelihood of achi...
...omen who are fit for PCS but are deemed u...
...delivered, all patients should have histol...
For NACT, a platinum/taxane doublet is recomme...
...tested surgery following three or four cycles...
...progressive disease on NACT have a poor...
...cal Evaluation and Treatment of Wome...